Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN51125379
ISRCTN51125379
Completed
Phase 1

Treating To Target in Type 2 diabetes

ovo Nordisk Limited (UK)0 sites700 target enrollmentSeptember 14, 2004
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsType 2 diabetesNutritional, Metabolic, EndocrineNon-insulin-dependent diabetes mellitus

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Type 2 diabetes
Sponsor
ovo Nordisk Limited (UK)
Enrollment
700
Status
Completed
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 14, 2004
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ovo Nordisk Limited (UK)

Eligibility Criteria

Inclusion Criteria

  • •Current inclusion criteria as of 06/07/2007:
  • •1\. Informed consent
  • •2\. People with type 2 diabetes for at least 12 months who are insulin naive
  • •3\. On maximally tolerated metformin and sulphonylurea therapy for at least four months
  • •4\. Males and females, aged 18 years or more
  • •5\. Body mass index of 40\.0 kg/m^2 or less
  • •6\. HbA1c in the range 7\.0 to 10\.0% inclusive
  • •7\. Able and willing to use insulin injections and perform self\-monitoring of plasma glucose for the entire trial period
  • •Previous inclusion criteria:
  • •1\. 700 subjects with type 2 diabetes

Exclusion Criteria

  • •Current exclusion criteria as of 06/07/2007:
  • •1\. Current or previous treatment with thiazolidinediones within the last six months
  • •2\. Current or previous treatment with an alpha\-glucosidase inhibitor, repaglinide or nateglinide within the past 30 days
  • •3\. Oral Antidiabetic (OAD) treatment with three or more OADs within the last six months
  • •4\. Diabetes other than type 2 diabetes mellitus
  • •5\. Known sight\-threatening retinopathy as judged by the investigator
  • •6\. Plasma creatinine 130 micromoles/l or more
  • •7\. Cardiac disease defined as:
  • •7\.1\. Unstable angina pectoris within the last six months
  • •7\.2\. Myocardial infarction (MI) within last six months

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
The DIAMOND for the Treatment of Type 2 Diabetes: Can Blood Triglycerides level be the predictor for therapy efficiency?Diabetes type 2 not controlled by oral medication.Therapeutic area: Body processes [G] - Physiological processes [G07]
EUCTR2013-001003-36-ATMetacure Ltd.45
Active, not recruiting
Not Applicable
4T studyTreating to Target in Type 2 DiabetesA 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin versus a Twice Daily Insulin Mixture versus a Meal-time Rapid-Acting Insulin in Subjects with Type 2 Diabetes Inadequately Controlled on Therapy with Oral Agents, and Assessing the Requirement for more Complex Insulin Regimens to Achieve and Maintain Glycaemic Control, their Efficacy and Durability
EUCTR2004-000514-38-IEovo Nordisk Pharmaceuticals Ltd700
Recruiting
Not Applicable
Clinical Research of Treatment of Type 2 Diabetes With Jianpi Huazhuo MassageType 2 Diabetes
ITMCTR2000003193anjing University of Chinese Medicine
Completed
Phase 3
Improved treatment of type 2 diabetes mellitus by improving the splenic functions and gastro intestinal tract using naturally occurring bioactive compoundsSplenic and gastro intestinal disorder in Type 2 Diabetes Mellitusgastrointestinal disorderDiabetes mellitusMetabolic diseasesMetabolic and Endocrine - Diabetes
ACTRN12614000007639guyen Van Toan94
Active, not recruiting
Phase 1
Individually tailored treatment in type 2 diabetesType 2 diabetesMedDRA version: 16.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Hormonal diseases [C19]
EUCTR2012-004883-23-DKHenning Beck-Nielsen